Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Randomized, double-blind, placebo-controlled phase III study of ixazomib plus lenalidomide-dexamethasone in patients with relapsed/refractory multiple myeloma: China Continuation study

Abstract Background The China Continuation study was a separate regional expansion of the global, double-blind, placebo-controlled, randomized phase III TOURMALINE-MM1 study of ixazomib plus lenalidomide–dexamethasone (Rd) in patients with relapsed/refractory multiple myeloma (RRMM) following one to...

Full description

Bibliographic Details
Main Authors: Jian Hou, Jie Jin, Yan Xu, Depei Wu, Xiaoyan Ke, Daobin Zhou, Jin Lu, Xin Du, Xiequn Chen, Junmin Li, Jing Liu, Neeraj Gupta, Michael J. Hanley, Hongmei Li, Zhaowei Hua, Bingxia Wang, Xiaoquan Zhang, Hui Wang, Helgi van de Velde, Paul G. Richardson, Philippe Moreau
Format: Article
Language:English
Published: BMC 2017-07-01
Series:Journal of Hematology & Oncology
Subjects:
China
Ixazomib
Multiple myeloma
Oral
Overall survival
Progression-free survival
Online Access:http://link.springer.com/article/10.1186/s13045-017-0501-4

Internet

http://link.springer.com/article/10.1186/s13045-017-0501-4

Similar Items